Matthew Baumgartner
About Matthew Baumgartner
Matthew Baumgartner is a Senior Investigator at Roivant Sciences in Boston, Massachusetts, where he has worked since 2021. He specializes in computational drug discovery and has a Ph.D. in Computational Biology from the University of Pittsburgh.
Work at Roivant Sciences
Matthew Baumgartner has been serving as a Senior Investigator at Roivant Sciences since 2021. He is based in Boston, Massachusetts. In this role, he focuses on developing methods for computational drug discovery, utilizing his expertise in molecular modeling and machine learning. His work contributes to advancing the company's research initiatives and drug development processes.
Previous Experience in Pharmaceutical Companies
Before joining Roivant Sciences, Baumgartner worked at The Janssen Pharmaceutical Companies of Johnson & Johnson as a Scientist in Computational Chemistry from 2020 to 2021. Prior to that, he was a Research Scientist in Computational Chemistry at Eli Lilly and Company from 2018 to 2020. He also held the position of Marie Curie Post Doctoral Fellow at Eli Lilly from 2016 to 2018, where he further developed his skills in computational methods for drug design.
Education and Expertise
Matthew Baumgartner earned his Doctor of Philosophy (Ph.D.) in Computational Biology from the University of Pittsburgh, where he studied from 2010 to 2016 under the advisement of Dr. Carlos Camacho. He also holds a Bachelor of Science (BS) in Biological Sciences from the same university, completed between 2008 and 2010. His educational background provides a strong foundation for his expertise in structure-based and ligand-based drug design, particularly for protein-protein interactions.
Research Focus and Methodologies
Baumgartner specializes in developing computational methods for drug discovery. His research includes molecular modeling and machine learning techniques. He has significant experience in structure-based and ligand-based drug design, focusing on therapeutically relevant protein-protein interactions. This expertise is critical for advancing drug discovery efforts in the pharmaceutical industry.